Targeting IL-1 in Sjögren's syndrome

Author： Yamada Akiko   Arakaki Rieko   Kudo Yasusei   Ishimaru Naozumi  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.17, Iss.4, 2013-04, pp. : 393-401

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting IL-1 in depression

By Maes Michael   Song Cai   Yirmiya Raz  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 11, 2012-11 ,pp. : 1097-1112

Informa Healthcare

Access to resources Recommend Favorite

Sjögren's syndrome

By Amarasena Roshan   Bowman Simon  

Clinical Medicine, Vol. 7, Iss. 1, 2007-01 ,pp. : 53-56

Royal College Of Physicians

Access to resources Recommend Favorite

Emerging biotherapies for Sjögren's syndrome

By Tobón Gabriel J   Saraux Alain   Pers Jacques-Olivier   Youinou Pierre  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 269-282

Informa Healthcare

Access to resources Recommend Favorite

Biologic Therapies in Primary Sjogren's Syndrome

By  

Current Pharmaceutical Biotechnology, Vol. 13, Iss. 10, 2012-08 ,pp. : 1997-2008

Bentham Science Publishers

Access to resources Recommend Favorite

Interleukin‐7 Enhances the Th1 Response to Promote the Development of Sjögren's Syndrome–like Autoimmune Exocrinopathy in Mice

By  

Arthritis & Rheumatism, Vol. 65, Iss. 8, 2013-08 ,pp. : 2132-2142

John Wiley & Sons Inc

Access to resources Recommend Favorite